LBT Innovations (ASX: LBT) has lodged a number of new international patent applications for its second automated diagnostics technology, the Automated Plate Assessment System (APAS).
Importantly, these latest patent lodgements will increase the commercial prospects of APAS, which automates the reading, reporting and sorting of culture plates in large microbiology laboratories.
The principal hardware and software elements of the technology will now be subjected to a series of examinations by an International Searching Authority.
The current applications bring to 14 the total number of patent and design families associated with the company’s APAS and PREVI® Isola technologies.
The PREVI® Isola automated pre-poured media streaker is a unit that boosts the efficiency of media processing tasks in clinical microbiology laboratories.
Patents covering the PREVI® Isola system have been granted in Australia, France, Germany, the United Kingdom, Italy, the Netherlands, Spain, New Zealand, China and the U.S., with applications pending in further countries.
Last month, LBT and international licensee bioMérieux agreed on a three year, US$600,000 minimum royalty on sales of disposable applicators for the PREVI® Isola system.
Under LBT's licence, bioMérieux is responsible for the global manufacture, sales and marketing of PREVI® Isola.
The system was launched in November 2008 with sales now achieved in laboratories in the U.S., Europe, UK, China, the Middle East, Asia Pacific and Australia.
bioMérieux doubled its installed base of PREVI® Isola systems during 2011, having announced the sale of the 100th PREVI® Isola earlier in the year.